Welcome! Login | Register
 

Dear John: No Affair. And Maybe No Friendship.—Was she wrong to tell her friends?

Davis Advertising Debuts Blog about Marketing to Millennials—Davis Advertising will take an in-depth look at…

BBB Warns Consumers of Online Retailer, shopZoey.com—Better Business Bureau is warning consumers about shopZoey.com,…

Smart Benefits: Are Double-Digit Premium Increases a Thing of the Past?—A new study on employer health benefits from…

College Admissions: Which New England Grads Make 6 Figures?—As more attention from the federal government focuses…

Vanna to Play at Worcester’s Palladium—Boston’s melodic hardcore group, Vanna, has announced they…

Defensive Dominance Gives Patriots Blowout Win in Minnesota—The New England Patriots traveled to Minnesota looking…

Revs Stay Red-Hot, Win Fifth Straight—It was a cool, rainy night at Gillette…

Best Apple Orchards of Southern New England—Mid-September is the best time of year for…

Urban Gardener: Hot Peppers And Picante—Urban gardeners are thrifty sorts who pack as…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.